Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 376
- Registration Number
- NCT04912167
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT04803175
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 264
- Registration Number
- NCT04800081
- Locations
- 🇨🇳
Department of Cardiology, Second Hospital of Lanzhou University, Lanzhou, GuSu, China
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Mark Ledwidge
- Target Recruit Count
- 250
- Registration Number
- NCT04687111
- Locations
- 🇮🇪
The STOP-HF Service, St Michael's Hosptial, Dun Laoghaire, Co Dublin, Ireland
🇮🇪St Vincents University Hospital, Dublin, Ireland
The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Amir Safwat
- Target Recruit Count
- 60
- Registration Number
- NCT04688294
- Locations
- 🇪🇬
Wadi El-Neel Hospital, Cairo, Egypt
Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2020-11-10
- Target Recruit Count
- 10
- Registration Number
- NCT04623866
- Locations
- 🇨🇳
The Children Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 341
- Registration Number
- NCT04606563
- Locations
- 🇨🇦
Royal Jubilee Hospital, Nanaimo, British Columbia, Canada
🇨🇦St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
A Study of LY900020 in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT04047940
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 467
- Registration Number
- NCT03988634
- Locations
- 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States
LCZ696 in Advanced LV Hypertrophy and HFpEF
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Target Recruit Count
- 60
- Registration Number
- NCT03928158
- Locations
- 🇷🇺
National Medical Research Center for Cardiology, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.